Skip to content
thestock.space

On 6 Nov 2026, Amrutanjan Health Care was priced at ₹514.45, or 27.6× trailing earnings, against an industry P/E of 28.7×, and the shares are 31% below their 52-week high. Sales and net profit grew 9.9% and 13% a year over 3 years, with ROCE of 20% and ROE of 17%. It carries very little debt, and its dividend yield is 1.0%. It is a small-cap company with a market cap of ₹1,487 Cr, ranked 63rd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 28% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹518.70
Day high
₹521.00
Day low
₹508.85
Prev. close
₹518.70
Volume
29.9K

Health check

2 good · 2 fair · 2 to check
  • ReturnsBehind

    −27.5% over a year, better than 0 of 7 peers.

  • Price tagIn line

    P/E 27.6 vs industry 28.7.

  • GrowthSteady

    Sales +9.9%, profit +13.3% a year over 3 years.

  • ProfitabilityStrong

    ROCE 20.4% vs peer median 17.9%.

  • Balance sheetSolid

    Practically debt-free.

  • Red flags2 to check

    Quarterly profit down 47.5% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹1,487 Cr, #63 of 154 in its industry by size.

Defensive

Beta 0.42 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹511 Cr · profit ₹54 Cr
Market cap
₹1,487 Cr
Small cap
P/E
27.6
Industry 28.7
Price to book
4.02
Peers 4.99
Dividend yield
0.98%
ROE
16.6%
Peers 14.7%
ROCE
20.4%
Peers 17.9%
Debt to equity
0.00
Debt ₹1.78 Cr
EPS (TTM)
₹18.67
Face value ₹1
OPM (TTM)
12.5%
Net margin 10.6%
Sales growth
+9.5%
Latest quarter vs a year ago
Profit growth
−47.5%
Latest quarter vs a year ago
Price to sales
2.91
EV/EBITDA 19.8

Strengths and risks

Strengths

  • Return on capital employed of 20.4%.
  • Practically debt-free.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 47.5% on a year ago.
  • 31% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Amrutanjan Health Care

Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products in India and internationally. It operates through OTC Products, Beverages, Women's Hygiene & Personal Care, and Others segments. The company provides pain management products comprising pain balms and roll-ons, back pain roll-ons, stick-on patch, and joint muscle sprays; dental pain gel; and decorn corn caps; hand sanitizer under the NOGerms…

Headquarters
Chennai
Employees
661
Sector
Healthcare
ISIN
INE098F01031
Website
amrutanjan.com

Price range

52 weeks

₹476.50₹744.00

Today

₹508.85₹521.00
Avg volume (3M)
82.9K
1-year return
minus 27.5%
From 52-week high
minus 30.9%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
AMRUTANJANAmrutanjan Health Care514.45minus 0.82%1,48727.64.02–14.6%2.2%––0.98%minus 27.5%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
94118141150103
85.610111613298.8
8.416.525.217.94.2
9.0%14.0%17.8%12.0%4.1%
4.44.34.14.73.8
0.10000
1.51.61.61.61.9
––−1.3––
11.319.226.4216.1
26.4%27.3%26.2%23.0%28.1%
8.31419.516.24.4
2.874.836.735.601.51

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+9.9%
Profit CAGR 3Y
+13.3%
EPS CAGR 3Y
+13.7%
ROE
16.6%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
378420451502
–+11.1%+7.2%+11.4%
331366390424
47.354.160.177.3
12.5%12.9%13.3%15.4%
11.914.81615.6
0.10.20.20.2
5.26.16.56.3
−0.2−0.8−0.2−8.5
53.661.969.177.9
25.7%27.4%26.5%25.6%
39.84550.857.9
–+12.9%+13.0%+13.9%
13.6315.5017.5820.03

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2.92.92.92.9
288286324367
0.91.72.11.8
70.476.792.7137
362367421509
47.749.679.7157
1.32.432107
42.711.541.445.8
190207195170
80.696.372.928.7
362367421509

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
20.227.950.936
−2.519.2−31−21.2
−15−48.3−13.5−13.6
2.7−1.26.41.1
−8.9−6.7−35.6−55
11.321.215.3−19
−14.4−13.4−13.3−13.2

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 10.5% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you